Home
Conditions
Immunoproliferative Disorders

Clinical trial condition

Immunoproliferative Disorders

Explore clinical trials studying Immunoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,001 public trials 2,038 recruiting studies

Refine in advanced search Browse all conditions

Immunoproliferative Disorders trial results

Active, not recruiting

Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)

NCT06400225

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +19 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, not recruiting

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

NCT05497804

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations: Mayo Clinic in Arizona Scottsdale, Arizona, United States

Mayo Clinic Jacksonville, Florida, United States

Mayo Clinic in Rochester Rochester, Minnesota, United States

View Trial Details

Active, not recruiting

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L)

NCT06385496

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +19 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, not recruiting

National Cancer Institute "Cancer Moonshot Biobank"

NCT04314401

Conditions: Acute Myeloid Leukemia, Adnexal Diseases, Anatomic Stage III Breast Cancer AJCC v8, +98 more
Locations: Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis Daphne, Alabama, United States

Thomas Hospital Fairhope, Alabama, United States

Mobile Infirmary Medical Center Mobile, Alabama, United States

Gulf Health Hospitals Inc/Infirmary Cancer Care - Saraland Saraland, Alabama, United States

View all 150 locations

View Trial Details

Active, not recruiting

Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M)

NCT06390865

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Blood Protein Disorders, +19 more
Locations: ECOG-ACRIN Cancer Research Group Philadelphia, Pennsylvania, United States

View Trial Details

Active, not recruiting

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

NCT03038672

Conditions: ALK-Positive Large B-Cell Lymphoma, Burkitt Lymphoma, DNA Virus Infections, +53 more
Locations: Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States

Mayo Clinic in Arizona Scottsdale, Arizona, United States

Mayo Clinic in Florida Jacksonville, Florida, United States

Moffitt Cancer Center-International Plaza Tampa, Florida, United States

View all 33 locations

View Trial Details

Active, not recruiting

Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma

NCT01703949

Conditions: Hemic and Lymphatic Diseases, Hodgkin Disease, Immune System Diseases, +11 more
Locations: Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Active, not recruiting

Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia

NCT04263480

Conditions: Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations: Uniklinikum Salzburg Salzburg, Austria

Medizinische Universität Wien Vienna, Austria

Vivantes Klinikum am Urban Berlin, Germany

Ev. Diakoniekrankenhaus Bremen, Germany

View all 17 locations

View Trial Details

Active, not recruiting

ASIA Down Syndrome Acute Lymphoblastic Leukemia 2016

NCT03286634

Conditions: Abnormalities, Multiple, Acute Lymphoblastic Leukemia, Childhood Cancer, +20 more
Locations: Prince of Wales Hospital Shatin, New Territories, Hong Kong

Kagoshima University Hospital Kagoshima, Japan

University of Malaya Medical Centre Kuala Lumpur, Malaysia

Subang Jaya Medical Centre Subang Jaya, Malaysia

View Trial Details

Active, not recruiting

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

NCT05453500

Conditions: B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Burkitt Lymphoma, DNA Virus Infections, +15 more
Locations: Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States

View Trial Details

Immunoproliferative Disorders

Immunoproliferative Disorders trial results

Related conditions